Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ventas, Inc. (NYSE: VTR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a healthcare-focused S&P 500 real estate investment trust. Through these filings, investors can review how Ventas reports on its portfolio of approximately 1,400 properties in North America and the United Kingdom, including senior housing communities, outpatient medical buildings, research centers and other healthcare facilities.
Current and historical Forms 8-K offer detailed information about material events affecting Ventas and its subsidiaries. Recent 8-K filings describe items such as the pricing and issuance of senior notes by Ventas Realty, Limited Partnership, amendments to unsecured term loan facilities guaranteed by Ventas, and announcements of quarterly results. These documents help readers understand the company’s capital structure, borrowing arrangements and operating performance disclosures.
Other SEC filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, provide broader context on Ventas’s business, risk factors, REIT structure and segment performance. For a healthcare REIT like Ventas, these reports typically include discussions of its senior housing operating portfolio, outpatient medical and research assets, and the demographic and regulatory environment relevant to its properties.
Investors can also use SEC filings to track matters such as dividend practices, debt covenants, and the terms of public offerings or credit agreements. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections and surface important changes across reporting periods, helping users interpret complex documents more efficiently. Real-time updates from the SEC’s EDGAR system mean that new Ventas filings, including 10-K, 10-Q, 8-K and related exhibits, are available promptly, while Form 4 and other ownership reports can be consulted to analyze insider transactions and equity-based compensation activity associated with VTR.
Ventas (VTR) Form 4: EVP & CFO Robert F. Probst exercised stock options for 33,591 shares at $73.71 on 11/12/2025 and sold 33,591 shares at a weighted average price of $76.7719, pursuant to a Rule 10b5-1 trading plan entered on February 19, 2025.
The options were fully vested, scheduled to expire within the next nine months, and relate to an award first exercisable on 08/03/2016 with an expiration date of 08/03/2026. Following the transactions, Probst directly beneficially owns 168,364 shares. The sale occurred across multiple trades at prices ranging from $76.71 to $76.9376.
VTR: A Form 144 notice discloses a proposed sale of up to 33,591 shares of common stock through Merrill Private Wealth, with an aggregate market value of 2,578,846.3. The approximate sale date is 11/12/2025 on the NYSE. The shares were acquired on 11/12/2025 via an exercise of employee stock options from the issuer using a broker-assisted cashless exercise.
Shares outstanding were 469,732,824; this is a baseline figure, not the amount being offered.
Ventas, Inc. (VTR) disclosed a Form 4 for officer Peter J. Bulgarelli, who sold 40 shares of common stock on 11/07/2025 at a $75.7013 weighted average, with trades ranging from $75.26 to $76.14. The transaction was executed under a Rule 10b5-1 trading plan entered on February 20, 2025.
Following the sale, Bulgarelli beneficially owns 111,488 shares, held directly.
Ventas, Inc. (VTR) received a Form 144 notice for a proposed sale of common stock. The notice covers 40 shares with an aggregate market value of $3,028.05, to be executed through Northern Trust Securities, Inc. The approximate sale date is 11/07/2025 on the NYSE.
The shares were acquired as compensation on 02/01/2023. The filing also lists recent transactions by the same seller over the past three months, including sales on 09/15/2025 (406 shares; $28,418.94), 09/30/2025 (2,040; $142,779.60), 10/01/2025 (2,554; $179,435.36), 11/04/2025 (3,924; $294,286.66), 11/05/2025 (870; $65,493.95), and 11/06/2025 (166; $12,475.48).
Ventas, Inc. (VTR) reported insider stock sales by Executive Vice President (EVP OM&R-Ventas/Pres&CEO-LHS) Peter J. Bulgarelli. The transactions were open‑market sales coded “S” and executed under a Rule 10b5‑1 trading plan entered on February 20, 2025.
He sold 3,924 shares on 11/04/2025 at a weighted average price of $74.9966 (range $74.99–$75.11), 870 shares on 11/05/2025 at $75.2804 (range $74.99–$75.5623), and 166 shares on 11/06/2025 at $75.1535 (range $75.01–$75.39). Following these transactions, he beneficially owns 111,528 shares, held directly.
Ventas (VTR) reported insider transactions by Chairman and CEO Debra A. Cafaro. On 11/04–11/06/2025, she exercised options at $63.24 for 11,452, 19,250, and 264 shares, then sold equal shares at weighted average prices of $75.0216, $75.2908, and $75.0489, pursuant to a Rule 10b5-1 plan entered on March 28, 2024. The options exercised were fully vested and scheduled to expire within the next 12 months. Following these trades, she directly owns 1,145,695 common shares and holds 82,582 unexercised options expiring on 11/02/2026.
Ventas, Inc. (VTR) received a Form 144 notice indicating an intended sale of 166 shares of common stock, with an aggregate market value $12,475.48. The proposed sale is listed through Northern Trust Securities, Inc. on or about 11/06/2025, and the shares trade on the NYSE. The seller acquired the shares on 02/01/2023 as compensation shares. Shares outstanding were 469,732,824.
Recent sales by the same seller include 406 shares for $28,418.94 on 09/15/2025 and 2,040 shares for $142,779.60 on 09/30/2025.
Ventas, Inc. (VTR) reported a Form 144 notice for a planned sale of 264 shares of common stock by Debra Cafaro. The filing lists an aggregate market value of $19,812.92, with an approximate sale date of 11/06/2025, to be executed through Merrill Lynch on the NYSE. The shares to be sold were acquired on 11/06/2025 via a broker-assisted exercise of employee stock options.
Recent activity disclosed includes prior sales over the past three months, such as 317,258 shares on 10/30/2025 for $23,554,765.13 and 219,515 shares on 10/20/2025 for $15,656,406.48. Shares outstanding were 469,732,824; this is a baseline figure, not the amount being sold.
Ventas, Inc. (VTR): Form 144 notice of proposed sale
Debra Cafaro filed to sell 19,250 shares of Ventas common stock, with an aggregate market value $1,449,348.10. The approximate sale date is November 5, 2025 on the NYSE, through Merrill Lynch. The shares were acquired the same day via a broker-assisted exercise of employee stock options. Ventas reported 469,732,824 shares outstanding.
Recent sales disclosed for the past three months include 317,258 shares on October 30, 2025 for $23,554,765.13 and 219,515 shares on October 20, 2025 for $15,656,406.48, among other smaller transactions.
Ventas, Inc. (VTR) filed a Form 144 indicating a proposed sale of 870 shares of common stock with an aggregate market value of $65,493.95. The filing lists Northern Trust Securities, Inc. as broker and an approximate sale date of 11/05/2025 on the NYSE. The shares were acquired as compensation on 02/01/2023.
Recent activity disclosed for the same seller includes sales of 406 shares for $28,418.94 on 09/15/2025, 2,040 shares for $142,779.60 on 09/30/2025, 2,554 shares for $179,435.36 on 10/01/2025, and 3,924 shares for $294,286.66 on 11/04/2025. Shares outstanding were 469,732,824 as of the filing’s reference line; this is a baseline figure, not the amount being offered.